340 related articles for article (PubMed ID: 32430395)
1. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances.
Alper BS; Foster G; Thabane L; Rae-Grant A; Malone-Moses M; Manheimer E
BMJ Evid Based Med; 2020 Oct; 25(5):168-171. PubMed ID: 32430395
[TBL] [Abstract][Full Text] [Related]
2. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
Bluhmki E; Chamorro A; Dávalos A; Machnig T; Sauce C; Wahlgren N; Wardlaw J; Hacke W
Lancet Neurol; 2009 Dec; 8(12):1095-102. PubMed ID: 19850525
[TBL] [Abstract][Full Text] [Related]
3. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
Gusev EI; Martynov MY; Nikonov AA; Shamalov NA; Semenov MP; Gerasimets EA; Yarovaya EB; Semenov AM; Archakov AI; Markin SS;
Lancet Neurol; 2021 Sep; 20(9):721-728. PubMed ID: 34418399
[TBL] [Abstract][Full Text] [Related]
4. Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis.
Stroke Thrombolysis Trialists' Collaborative Group
Int J Stroke; 2013 Jun; 8(4):278-83. PubMed ID: 23639145
[TBL] [Abstract][Full Text] [Related]
5. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data.
Thomalla G; Boutitie F; Ma H; Koga M; Ringleb P; Schwamm LH; Wu O; Bendszus M; Bladin CF; Campbell BCV; Cheng B; Churilov L; Ebinger M; Endres M; Fiebach JB; Fukuda-Doi M; Inoue M; Kleinig TJ; Latour LL; Lemmens R; Levi CR; Leys D; Miwa K; Molina CA; Muir KW; Nighoghossian N; Parsons MW; Pedraza S; Schellinger PD; Schwab S; Simonsen CZ; Song SS; Thijs V; Toni D; Hsu CY; Wahlgren N; Yamamoto H; Yassi N; Yoshimura S; Warach S; Hacke W; Toyoda K; Donnan GA; Davis SM; Gerloff C;
Lancet; 2020 Nov; 396(10262):1574-1584. PubMed ID: 33176180
[TBL] [Abstract][Full Text] [Related]
6. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: the first multicentre, phase III trial in China.
Zheng H; Yang Y; Chen H; Li C; Chen Y; Shi FD; Yang L; Cui X; Lu Z; Liang Y; Cui S; Xu A; Wu Y; Sun Y; Wang Y
Stroke Vasc Neurol; 2020 Sep; 5(3):285-290. PubMed ID: 32467323
[TBL] [Abstract][Full Text] [Related]
7. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.
Hacke W; Kaste M; Fieschi C; von Kummer R; Davalos A; Meier D; Larrue V; Bluhmki E; Davis S; Donnan G; Schneider D; Diez-Tejedor E; Trouillas P
Lancet; 1998 Oct; 352(9136):1245-51. PubMed ID: 9788453
[TBL] [Abstract][Full Text] [Related]
8. Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial.
Chen HS; Cui Y; Zhou ZH; Zhang H; Wang LX; Wang WZ; Shen LY; Guo LY; Wang EQ; Wang RX; Han J; Dong YL; Li J; Lin YZ; Yang QC; Zhang L; Li JY; Wang J; Xia L; Ma GB; Lu J; Jiang CH; Huang SM; Wan LS; Piao XY; Li Z; Li YS; Yang KH; Wang DL; Nguyen TN;
JAMA; 2023 Jun; 329(24):2135-2144. PubMed ID: 37367978
[TBL] [Abstract][Full Text] [Related]
9. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.
Emberson J; Lees KR; Lyden P; Blackwell L; Albers G; Bluhmki E; Brott T; Cohen G; Davis S; Donnan G; Grotta J; Howard G; Kaste M; Koga M; von Kummer R; Lansberg M; Lindley RI; Murray G; Olivot JM; Parsons M; Tilley B; Toni D; Toyoda K; Wahlgren N; Wardlaw J; Whiteley W; del Zoppo GJ; Baigent C; Sandercock P; Hacke W;
Lancet; 2014 Nov; 384(9958):1929-35. PubMed ID: 25106063
[TBL] [Abstract][Full Text] [Related]
10. Treatment with intravenous alteplase in ischaemic stroke patients with onset time between 4.5 and 24 hours (HOPE): protocol for a randomised, controlled, multicentre study.
Luo Z; Zhou Y; He Y; Yan S; Chen Z; Zhang X; Chen Y; Tong LS; Zhong W; Hu H; Zhang K; Yang J; Campbell BCV; Lou M
Stroke Vasc Neurol; 2024 Jun; 9(3):318-323. PubMed ID: 37527920
[TBL] [Abstract][Full Text] [Related]
11. Intravenous thrombolysis with 0.9 mg/kg alteplase for acute ischaemic stroke: a network meta-analysis of treatment delay.
Chen X; Shen Y; Huang C; Geng Y; Yu Y
Postgrad Med J; 2020 Nov; 96(1141):680-685. PubMed ID: 31857497
[TBL] [Abstract][Full Text] [Related]
12. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
Khatri P; Kleindorfer DO; Devlin T; Sawyer RN; Starr M; Mejilla J; Broderick J; Chatterjee A; Jauch EC; Levine SR; Romano JG; Saver JL; Vagal A; Purdon B; Devenport J; Pavlov A; Yeatts SD;
JAMA; 2018 Jul; 320(2):156-166. PubMed ID: 29998337
[TBL] [Abstract][Full Text] [Related]
13. Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial.
IST-3 collaborative group
Lancet Neurol; 2015 May; 14(5):485-96. PubMed ID: 25819484
[TBL] [Abstract][Full Text] [Related]
14. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.
Anderson CS; Huang Y; Lindley RI; Chen X; Arima H; Chen G; Li Q; Billot L; Delcourt C; Bath PM; Broderick JP; Demchuk AM; Donnan GA; Durham AC; Lavados PM; Lee TH; Levi C; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Silva F; Song L; Thang NH; Wardlaw JM; Wang JG; Wang X; Woodward M; Chalmers J; Robinson TG;
Lancet; 2019 Mar; 393(10174):877-888. PubMed ID: 30739745
[TBL] [Abstract][Full Text] [Related]
15. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
[TBL] [Abstract][Full Text] [Related]
16. Effect of Time to Thrombolysis on Clinical Outcomes in Patients With Acute Ischemic Stroke Treated With Tenecteplase Compared to Alteplase: Analysis From the AcT Randomized Controlled Trial.
Singh N; Almekhlafi MA; Bala F; Ademola A; Coutts SB; Deschaintre Y; Khosravani H; Buck B; Appireddy R; Moreau F; Gubitz G; Tkach A; Catanese L; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar JJ; Ghrooda E; Poppe AY; Williams H; Field TS; Manosalva A; Siddiqui MM; Zafar A; Imoukhoude O; Hunter G; Shamy M; Demchuk AM; Claggett BL; Hill MD; Sajobi TT; Swartz RH; Menon BK
Stroke; 2023 Nov; 54(11):2766-2775. PubMed ID: 37800372
[TBL] [Abstract][Full Text] [Related]
17. Association of Reperfusion After Thrombolysis With Clinical Outcome Across the 4.5- to 9-Hours and Wake-up Stroke Time Window: A Meta-Analysis of the EXTEND and EPITHET Randomized Clinical Trials.
Campbell BCV; Ma H; Parsons MW; Churilov L; Yassi N; Kleinig TJ; Hsu CY; Dewey HM; Butcher KS; Yan B; Desmond PM; Wijeratne T; Curtze S; Barber PA; De Silva DA; Thijs V; Levi CR; Bladin CF; Sharma G; Bivard A; Donnan GA; Davis SM
JAMA Neurol; 2021 Feb; 78(2):236-240. PubMed ID: 33137171
[TBL] [Abstract][Full Text] [Related]
18. Tenecteplase versus alteplase for stroke thrombolysis evaluation (TASTE): A multicentre, prospective, randomized, open-label, blinded-endpoint, controlled phase III non-inferiority trial protocol.
Bivard A; Garcia-Esperon C; Churilov L; Spratt N; Russell M; Campbell BC; Choi P; Kleinig T; Ma H; Markus H; Molina C; Hsu C; Tsai CH; Meretoja A; Strbian D; Butcher K; Wu T; Davis S; Donnan G; Levi C; Parsons M
Int J Stroke; 2023 Jul; 18(6):751-756. PubMed ID: 36655938
[TBL] [Abstract][Full Text] [Related]
19. Dual thrombolytic therapy with mutant pro-urokinase and small bolus alteplase for ischemic stroke (DUMAS): study protocol for a multicenter randomized controlled phase II trial.
van der Ende NAM; Roozenbeek B; Smagge LEM; Luijten SPR; Aerden LAM; Kraayeveld P; van den Wijngaard IR; Lycklama À Nijeholt GJ; den Hertog HM; Flach HZ; Wallace AC; Gurewich V; Del Zoppo GJ; Meurer WJ; Lingsma HF; van der Lugt A; Dippel DWJ;
Trials; 2022 Aug; 23(1):641. PubMed ID: 35945566
[TBL] [Abstract][Full Text] [Related]
20. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
Kvistad CE; Næss H; Helleberg BH; Idicula T; Hagberg G; Nordby LM; Jenssen KN; Tobro H; Rörholt DM; Kaur K; Eltoft A; Evensen K; Haasz J; Singaravel G; Fromm A; Thomassen L
Lancet Neurol; 2022 Jun; 21(6):511-519. PubMed ID: 35525250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
